Stock Analysis

Alpha IVF Group Berhad Full Year 2024 Earnings: EPS: RM0.012 (vs RM0.015 in FY 2023)

Simply Wall St

July 22, 2024

Alpha IVF Group Berhad (KLSE:ALPHA) Full Year 2024 Results

Key Financial Results

Revenue: RM167.6m (up 22% from FY 2023).
Net income: RM52.9m (flat on FY 2023).
Profit margin: 32% (down from 39% in FY 2023). The decrease in margin was driven by higher expenses.
EPS: RM0.012 (down from RM0.015 in FY 2023).

revenue-and-expenses-breakdown — KLSE:ALPHA Revenue and Expenses Breakdown July 22nd 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Alpha IVF Group Berhad Earnings Insights

The primary driver behind last 12 months revenue was the Malaysia segment contributing a total revenue of RM135.5m (81% of total revenue). The largest operating expense was General & Administrative costs, amounting to RM24.5m (55% of total expenses). Explore how ALPHA's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Healthcare industry in Malaysia.

Performance of the Malaysian Healthcare industry.

The company's shares are up 3.1% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 1 warning sign for Alpha IVF Group Berhad that you should be aware of.

Valuation is complex, but we're helping make it simple.

Find out whether Alpha IVF Group Berhad is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.